Vaxcyte, Inc. (PCVX) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $61.92 (-1.11%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 25, 2026 | Tom Shrader | BTIG | $89.00 | +43.7% |
| Nov 19, 2025 | David Risinger | Leerink Partners | $77.00 | +24.3% |
| Nov 6, 2024 | Roger Song | Jefferies | $146.00 | +135.8% |
| Nov 6, 2024 | David Risinger | Leerink Partners | $135.00 | +118.0% |
| Sep 10, 2024 | Salim Syed | Mizuho Securities | $163.00 | +163.2% |
| Sep 4, 2024 | Jason Gerberry | Bank of America Securities | $140.00 | +126.1% |
| Sep 3, 2024 | David Risinger | Leerink Partners | $153.00 | +147.1% |
| Sep 3, 2024 | Tom Shrader | BTIG | $160.00 | +158.4% |
| Sep 3, 2024 | Roger Song | Jefferies | $129.00 | +108.3% |
| Sep 3, 2024 | Salim Syed | Mizuho Securities | $113.00 | +82.5% |
| Aug 7, 2024 | Tom Shrader | BTIG | $98.00 | +58.3% |
Top Analysts Covering PCVX
PCVX vs Sector & Market
| Metric | PCVX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.41 |
| Analyst Count | 6 | 8 | 19 |
| Target Upside | +97.5% | +153002.0% | +21.5% |
| P/E Ratio | -10.43 | 3.48 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $13M | $13M | $13M | 1 |
| 2027-12-31 | $27M | $27M | $27M | 7 |
| 2028-12-31 | $217M | $217M | $217M | 7 |
| 2029-12-31 | $1.53B | $1.53B | $1.53B | 3 |
| 2030-12-31 | $2.56B | $2.56B | $2.56B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-1.96 | $-1.96 | $-1.96 | 1 |
| 2027-12-31 | $-10.20 | $-7.09 | $-4.90 | 5 |
| 2028-12-31 | $-10.38 | $-6.29 | $-4.65 | 6 |
| 2029-12-31 | $1.55 | $1.55 | $1.55 | 4 |
| 2030-12-31 | $6.90 | $6.90 | $6.90 | 2 |
Frequently Asked Questions
What is the analyst consensus for PCVX?
The consensus among 6 analysts covering Vaxcyte, Inc. (PCVX) is Buy with an average price target of $105.57.
What is the highest price target for PCVX?
The highest price target for PCVX is $163.00, set by Salim Syed at Mizuho Securities on 2024-09-10.
What is the lowest price target for PCVX?
The lowest price target for PCVX is $77.00, set by David Risinger at Leerink Partners on 2025-11-19.
How many analysts cover PCVX?
6 analysts have issued ratings for Vaxcyte, Inc. in the past 12 months.
Is PCVX a buy or sell right now?
Based on 6 analyst ratings, PCVX has a consensus rating of Buy (2.00/5) with a +97.5% upside to the consensus target of $105.57.
What are the earnings estimates for PCVX?
Analysts estimate PCVX will report EPS of $-1.96 for the period ending 2026-12-31, with revenue estimated at $13M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.